Vygon has acquired Stiletto, a new generation of extended‑dwell catheters integrating SlipStream technology, from Salt Lake City-based Avia Vascular. The deal aims to enhance Vygon’s leadership in vascular access and accelerate growth in the United States, where extended-dwell catheters represent a significant and rapidly expanding market segment.

Neither company disclosed financial details for the transaction.
 
The Stiletto Extended Dwell Catheter (EDC) is a sterile, peripherally inserted single‑use device designed for mid‑duration therapies (less than 28 days). SlipStream is a patented insertion system designed to replace the traditional Seldinger technique for extended‑dwell catheters.
 
“Stiletto closes a critical gap in our vascular access offering,” said Thomas Walter, Vygon’s chief corporate officer, International Business & Offer Development. “Its SlipStream technology will reshape the way extended‑dwell catheters are inserted, presenting clinicians with a safer, more intuitive technique and delivering significant improvements in patient comfort, safety and care efficiency, fully aligned with Vygon’s mission to Value Life.”
 
By eliminating guidewires and reducing procedural steps, SlipStream offers clinicians a simpler, safer and more intuitive technique, while delivering significant clinical benefits for patients.
 
“This acquisition is a decisive step for Vygon as it enhances our leadership in vascular access,” Vygon CEO Ludovic Richard‑Vitton, stated. “By integrating Stiletto into our portfolio, we reinforce our position in this sector, significantly strengthening it in the U.S., the world’s largest and most dynamic market for midline and extended‑dwell catheters.”
  
The Stiletto purchase marks Vygon’s first entry into the extended-dwell catheter segment. Vygon now offers a comprehensive vascular access portfolio, covering a full continuum of solutions including standard midlines, extended‑dwell catheters, PICC lines, central venous catheters (CVC), implantable ports, and neonatal and pediatric vascular access devices.
 
The global market for midline and extended‑dwell catheter solutions was estimated at more than $3 billion in 2024, and is expected to grow between 6% and 9% through 2030. North America dominated the midline catheters market with the largest revenue share (40.31%) in 2024. The extended-dwell catheter segment is particularly dynamic, driven by the growing need for mid‑term venous access solutions that combine clinical efficiency, safety and cost‑effectiveness, according to the company.
 
Vygon designs, manufactures and markets single-use medical devices and active medical devices for healthcare professionals in hospitals and for private and independent practitioners. The company combines local and international in-depth expertise and know-how in each individual field. With expertise across the entire value chain, from product design to the delivery of training for medical personnel, Vygon provides healthcare professionals with effective products tailored to their needs and those of their patients, for optimal use and safety. Through its network of 26 subsidiaries and 400 distributors, Vygon distributes more than 205 million products annually in over 120 countries. Vygon is a Ecouen, France-based family-owned company founded in 1962 Paris that employs more than 2,700 staff worldwide. The turnover in 2024 was €418 million, with 81% of this derived from Vygon’s international business.